Strater is a sympathomimetic drug of Central action, which improves metabolism of the brain. You can order strattera here.
1 capsule contains: active substance: Atomoxetine (in the form of hydrochloride) 10 mg, 18 mg, 25 mg, 40 mg or 60 mg; auxiliary components: starch pregelatinization, Dimethicone; the composition of the shell: sodium lauryl sulfate, titanium dioxide, gelatin. Additionally, the composition of the shell capsules dosage: 18 mg – dye iron oxide yellow; 25 mg – Indigo Carmine dye; 40 mg – Indigo Carmine dye; 60 mg – dye iron oxide yellow, Indigo Carmine dye.
Pharmacodynamics and pharmacokinetics Strater is a sympathomimetic Central action, which includes a highly active component of Atomoxetine. He belongs to the group of inhibitors of the presynaptic norepinephrine transporters. The affinity of the drug for other receptors noradrenergic or other transporters or receptors of neurotransmitters is minimal. Strater does not apply to psychoactive drugs and a derivative of amphetamine. Clinical studies have not confirmed the greater severity of symptoms or other negative effects due to the withdrawal syndrome after completing treatment.
The ingestion ofAtomoxetine almost completely and with a high rate absorbed in the digestive tract. While food does not affect its impact on the body. The maximum concentration of the substance in the plasma is recorded already in 60-120 minutes. Atomoxetine quickly begins to circulate throughout the body and is well bound to plasma proteins, especially albumin. In the first stage of Atomoxetine metabolized in liver by CYP2D6 isoenzyme, and as the main metabolite excreted actively glukuroniziruyutza connection 4-hydroxyatomoxetine. This substance in its pharmacologic action is similar to Atomoxetine, however, the plasma is contained in a lower concentration. Patients with small activity of CYP2D6 4-hydroxyatomoxetine is synthesized with the participation of other enzymes in the cytochrome P450, but the process is longer. Atomoxetine does not increase the cycle and is not an inhibitor of CYP2D6.
At intake, the approximate half-life of this substance in patients with intense metabolism is 3.6 hours, and in patients with a slow metabolism for 21 hours. Atomoxetine in the form of a 4-hydroxyatomoxetine-O-glucuronide is predominantly excreted via the kidneys. In children older than 6 years the pharmacokinetics of the drug are identical pharmacokinetics in adult patients. Indications for use Application Strattera indicated for attention deficit disorder with hyperactivity (ADHD) in patients older than 6 years. Contraindications severe forms of heart disease; concomitant use of monoamine oxidase inhibitors (MAO); angle-closure glaucoma; hypersensitivity to the drug.